| Literature DB >> 23888198 |
Panagiotis Zis1, Stavros Dimopoulos, Vasiliki Markaki, Antonios Tavernarakis, Serafim Nanas.
Abstract
Cardiovascular adverse events in patients with myasthenia gravis (MG) are rare, but the early recognition of such events is crucial. We describe a case of a non-coronary myocardial infarction (MI) during the initial treatment period with pyridostigmine bromide in a female patient with MG. Clinicians should be cautious about the appearance of potential MI in patients with MG. A baseline electrocardiogram is advocated, when the early recognition of the MI clinical signs and the laboratory findings (myocardial markers) are vital to the immediate and appropriate management of this medical emergency, as well as to prevent future cardiovascular events. In this case report possible causes of myocardial adverse events in the context of MG, which may occur during the ongoing treatment and the clinical course of the disease, are discussed.Entities:
Keywords: Myasthenia gravis; Myocardial infarction; Pyridostigmine
Year: 2013 PMID: 23888198 PMCID: PMC3722426 DOI: 10.4330/wjc.v5.i7.265
Source DB: PubMed Journal: World J Cardiol